Thomas Hanke


Head of Academic Partnerships at Evotec. 

Since November 2016, Thomas has been responsible for strategic academic partnerships at Evotec. From November 2013, Thomas has been EVP of Immunology and Inflammation, heading a portfolio of drug discovery projects in the areas of inflammation and immuno-oncology at Evotec. During this time, Thomas’ focus has been on building high-value, performance based drug discovery alliances with academia and pharma.

From 2007 to 2013, Thomas was Sourcing Director at the Biopharmaceuticals Research Unit of Novo Nordisk, where he identified and evaluated multiple partnering opportunities related to compounds, targets and technologies for several therapeutic areas.

Prior to joining Novo Nordisk, Thomas was co-founder and Chief Scientific Officer at TeGenero, a German biotech company developing therapeutic monoclonal antibodies.

As LAB282 EIR, Thomas works closely with academics and with Oxford University Innovation to source and manage funded projects.